PPARGC1A and Menkes disease: Although no curative treatment is yet available for MD, preclinical evidence from animal and in vitro studies suggests that promoting the increase in mitochondrial content or mitochondrial biogenesis, through the activation of peroxisome proliferator-activated receptor gamma co-activator 1-alpha (PGC-1α) might be a therapeutic option (8, 9).